ePT--the Electronic Newsletter of Pharmaceutical Technology, May 19, 2011 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

ePT--the Electronic Newsletter of Pharmaceutical Technology, May 19, 2011
News
Teva Acquires Majority Stake in Taiyo
By Erik Greb
Teva Pharmaceutical Industries agreed to pay shareholders $460 million in cash to acquire a 57% stake in Taiyo Pharmaceutical Industry. Teva also will offer to buy all outstanding shares of Taiyo.
FDA Approvals of Biopharmaceuticals on the Rise
By Angie Drakulich
Regulatory approvals for new biopharmaceuticals in the United States have nearly doubled in the past decade compared with the 1990s, says a Tufts study.
J&J to Recall Select Lots of Prezista Due to Possible TBA Contamination
By Patricia Van Arnum
Johnson & Johnson subsidiary Janssen-Cilag International reported that the company is working with regulatory authorities in five countries to address trace amounts of 2,4,6- tribromoanisole identified in five batches of the HIV/AIDS medicine Prezista.
House Introduces Bill on Regenerative Medicine
By Amy Ritter
A bill was introduced in the US House of Representatives to launch a national strategy for the development of regenerative medicines.
Amylin Sues Eli Lilly for Alleged Anticompetitive Activity
By Stephanie Sutton
Amylin Pharmaceuticals has filed a lawsuit against Eli Lilly, alleging that Lilly is engaging in anticompetitive activity and breaching its agreements with Amylin to maximize commercialization of the drug, exenatide.
Week of May 19, 2011: Company and People Notes: AstraZeneca, GlaxoSmithKline, and the University of Manchester form new research collaboration for inflammation; BASi names Michael Zhou as senior director of R&D; and More.
AstraZeneca, GlaxoSmithKline, and the University of Manchester form new research collaboration for inflammation; BASi names Michael Zhou as senior director of R&D; and More.
Regulatory Roundup: EMA monitors Japanese-manufactured medicines following radiation leak from nuclear power plant
EMA is working with its European and international regulatory partners to monitor and evaluate ?the possible risk of radioactive contamination of medicines manufactured in Japan following the radiation leak from the Fukushima Daiichi nuclear power plant.?

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Click here